Literature DB >> 22113358

Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients.

Mie Kurata1, Takafumi Okura, Yoshiaki Kumon, Masahiko Tagawa, Hideaki Watanabe, Toshinori Nakahara, Tatsuhiko Miyazaki, Jitsuo Higaki, Masato Nose.   

Abstract

Atherothrombosis is the primary pathophysiology that underlies ischemic cerebral infarction. Osteopontin (OPN) is produced in atherosclerotic lesions and is cleaved by activated thrombin. We hypothesized that the rupture or damage of an unstable atherosclerotic plaque increases plasma levels of thrombin-cleaved OPN (trOPN). This study included 90 patients who received carotid angioplasty with stenting (CAS), 23 patients with essential hypertension (EHT) and 10 patients who were treated with carotid endarterectomy (CEA). The CAS patient group included 36 patients that had pre- and post-operative blood tests, diffusion-weighted imaging (DWI) using cerebral MRIs and estimated thrombus debris within the protection device. Immunohistochemistry of CEA specimens revealed that trOPN was detected around intra-plaque vessels. The highest tertile of plasma trOPN levels in CAS patients was higher than trOPN levels in EHT patients. Post-operative trOPN levels were significantly higher in symptomatic compared with asymptomatic patients (P=0.003). New ipsilateral DWI-positive patients revealed higher post-operative trOPN levels (P=0.003) and a higher grade of thrombi (P<0.001) than DWI-negative patients. TrOPN may be a novel biomarker that reflects the atherothrombotic status in ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113358     DOI: 10.1038/hr.2011.177

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Elevated levels of full-length and thrombin-cleaved osteopontin during acute dengue virus infection are associated with coagulation abnormalities.

Authors:  Haorile Chagan-Yasutan; Talitha Lea Lacuesta; Lishomwa C Ndhlovu; Shigeru Oguma; Prisca Susan A Leano; Elizabeth Freda O Telan; Toru Kubo; Kouichi Morita; Toshimitsu Uede; Efren M Dimaano; Toshio Hattori
Journal:  Thromb Res       Date:  2014-05-14       Impact factor: 3.944

2.  Plasma thrombin-cleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke.

Authors:  Saya Ozaki; Mie Kurata; Yoshiaki Kumon; Shirabe Matsumoto; Masahiko Tagawa; Hideaki Watanabe; Shiro Ohue; Jitsuo Higaki; Takanori Ohnishi
Journal:  Hypertens Res       Date:  2016-08-25       Impact factor: 3.872

3.  Silent brain infarcts on diffusion-weighted imaging after carotid revascularisation: A surrogate outcome measure for procedural stroke? A systematic review and meta-analysis.

Authors:  Christopher Traenka; Stefan T Engelter; Martin M Brown; Joanna Dobson; Chris Frost; Leo H Bonati
Journal:  Eur Stroke J       Date:  2019-01-15

4.  Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty.

Authors:  Hannah Slovacek; Rajan Khanna; Pavel Poredos; Mateja Jezovnik; Debra Hoppensteadt; Jawed Fareed; William Hopkinson
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 5.  The Yin-Yang of osteopontin in nervous system diseases: damage versus repair.

Authors:  Giuseppe Cappellano; Domizia Vecchio; Luca Magistrelli; Nausicaa Clemente; Davide Raineri; Camilla Barbero Mazzucca; Eleonora Virgilio; Umberto Dianzani; Annalisa Chiocchetti; Cristoforo Comi
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

Review 6.  Osteopontin as a candidate of therapeutic application for the acute brain injury.

Authors:  Yunxiang Zhou; Yihan Yao; Lesang Sheng; Jianmin Zhang; John H Zhang; Anwen Shao
Journal:  J Cell Mol Med       Date:  2020-07-13       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.